Compare Amgen, Inc. (AMGN) vs CubeSmart (CUBE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs CubeSmart — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while CubeSmart trades at $40.16 (market cap $9.10B). The key difference: Amgen, Inc. is far larger — about 21.6× CubeSmart's market cap, and CubeSmart pays the higher dividend (5.27%). Which is the better fit depends on your goals.
| AMGN | CUBE | |
|---|---|---|
Market Cap | $196.12B | $9.10B |
Sector | Health | Real Estate |
52-Week High | $388.16 | $42.34 |
52-Week Low | $271.18 | $35.36 |
Enterprise Value | $241.41B | $12.60B |
Dividend Yield | 2.77% | 5.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
CubeSmart (CUBE) trades at $40.19, up 1.01% with a bearish technical signal despite recent earnings beats. The REIT maintains strong profitability with 28.93% net margins and offers a 5.3% dividend yield. Analyst consensus shows mixed sentiment with 41% buy ratings but a $43.86 price target suggesting 9% upside. Recent news highlights Q2 2026 earnings anticipation on July 30, 2026, while institutional investors have been trimming positions.
The stock presents value with reasonable valuation multiples (P/E 28.1, P/S 8.13) and consistent cash flow generation, though high debt levels and interest rate sensitivity pose risks. Near-term performance will depend on Q2 earnings results and macroeconomic conditions affecting the self-storage sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →
